Literature DB >> 17934095

Amplifying elements of arthritis and joint destruction.

Wim B van den Berg1, Peter L van Lent, Leo A B Joosten, Shahla Abdollahi-Roodsaz, Marije I Koenders.   

Abstract

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterised by chronic joint inflammation and variable degrees of bone and cartilage erosion. Studies in animal models of arthritis provide insight into elements which can amplify destructive features. The presence of immune complexes in the joint makes arthritis more erosive. Although considerable bone erosion still occurs in the absence of FcgammaR triggering by immune complexes, through cytokine-induced RANKL and direct osteoclast activation, cartilage erosion is heavily dependent on the FcgammaR pathway. T cell factors such as IFNgamma and IL17 further amplify erosion through upregulation of the damaging FcgammaRI and stimulation of the influx of granulocytes, respectively. Apart from immune elements, environmental pressure and components of tissue damage contribute through innate pathways. Spontaneous T cell-dependent arthritis in IL1Ra-/- mice is absent under germ-free conditions, and markedly suppressed in TLR4-deficient mice. Moreover, TLR4 blocking with a receptor antagonist suppresses erosive arthritis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17934095      PMCID: PMC2095284          DOI: 10.1136/ard.2007.079830

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  19 in total

1.  Requirement of IL-17 receptor signaling in radiation-resistant cells in the joint for full progression of destructive synovitis.

Authors:  Erik Lubberts; Paul Schwarzenberger; Weitao Huang; Jill R Schurr; Jacques J Peschon; Wim B van den Berg; Jay K Kolls
Journal:  J Immunol       Date:  2005-09-01       Impact factor: 5.422

2.  ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro.

Authors:  Heather Stanton; Fraser M Rogerson; Charlotte J East; Suzanne B Golub; Kate E Lawlor; Clare T Meeker; Christopher B Little; Karena Last; Pamela J Farmer; Ian K Campbell; Anne M Fourie; Amanda J Fosang
Journal:  Nature       Date:  2005-03-31       Impact factor: 49.962

3.  Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1.

Authors:  Marije I Koenders; Erik Lubberts; Birgitte Oppers-Walgreen; Liduine van den Bersselaar; Monique M Helsen; Franco E Di Padova; Annemieke M H Boots; Hermann Gram; Leo A B Joosten; Wim B van den Berg
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

4.  Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis.

Authors:  Shahla Abdollahi-Roodsaz; Leo A B Joosten; Mieke F Roelofs; Timothy R D J Radstake; Giovanni Matera; Calin Popa; Jos W M van der Meer; Mihai G Netea; Wim B van den Berg
Journal:  Arthritis Rheum       Date:  2007-09

5.  Joint inflammation and chondrocyte death become independent of Fcgamma receptor type III by local overexpression of interferon-gamma during immune complex-mediated arthritis.

Authors:  K C A M Nabbe; P Boross; A E M Holthuysen; A W Sloëtjes; J K Kolls; S Verbeek; P L E M van Lent; W B van Den Berg
Journal:  Arthritis Rheum       Date:  2005-03

6.  IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist.

Authors:  Susumu Nakae; Shinobu Saijo; Reiko Horai; Katsuko Sudo; Shigeo Mori; Yoichiro Iwakura
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-29       Impact factor: 11.205

7.  FcgammaRI up-regulation induced by local adenoviral-mediated interferon-gamma production aggravates chondrocyte death during immune complex-mediated arthritis.

Authors:  Karin C Nabbe; Peter L van Lent; Astrid E Holthuysen; Jay K Kolls; Sjef Verbeek; Wim B van den Berg
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

8.  Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.

Authors:  Erik Lubberts; Marije I Koenders; Birgitte Oppers-Walgreen; Liduine van den Bersselaar; Christina J J Coenen-de Roo; Leo A B Joosten; Wim B van den Berg
Journal:  Arthritis Rheum       Date:  2004-02

9.  Coordinate expression of activating Fc gamma receptors I and III and inhibiting Fc gamma receptor type II in the determination of joint inflammation and cartilage destruction during immune complex-mediated arthritis.

Authors:  K C A M Nabbe; A B Blom; A E M Holthuysen; P Boross; J Roth; S Verbeek; P L E M van Lent; W B van den Berg
Journal:  Arthritis Rheum       Date:  2003-01

Review 10.  Proteoglycan-induced arthritis: immune regulation, cellular mechanisms, and genetics.

Authors:  Tibor T Glant; Alison Finnegan; Katalin Mikecz
Journal:  Crit Rev Immunol       Date:  2003       Impact factor: 2.214

View more
  20 in total

Review 1.  TLRs, future potential therapeutic targets for RA.

Authors:  Hatem A Elshabrawy; Abdul E Essani; Zoltán Szekanecz; David A Fox; Shiva Shahrara
Journal:  Autoimmun Rev       Date:  2016-12-15       Impact factor: 9.754

2.  Murine visceral leishmaniasis: IgM and polyclonal B-cell activation lead to disease exacerbation.

Authors:  Eszter Deak; Asha Jayakumar; Ka Wing Cho; Karen Goldsmith-Pestana; Blaise Dondji; John D Lambris; Diane McMahon-Pratt
Journal:  Eur J Immunol       Date:  2010-05       Impact factor: 5.532

3.  A benzamide-linked small molecule NDMC101 inhibits NFATc1 and NF-κB activity: a potential osteoclastogenesis inhibitor for experimental arthritis.

Authors:  Chia-Pi Cheng; Hsu-Shan Huang; Yu-Chieh Hsu; Ming-Jen Sheu; Deh-Ming Chang
Journal:  J Clin Immunol       Date:  2012-02-23       Impact factor: 8.317

4.  Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma.

Authors:  Kavita M Dhodapkar; Scott Barbuto; Phillip Matthews; Anjli Kukreja; Amitabha Mazumder; David Vesole; Sundar Jagannath; Madhav V Dhodapkar
Journal:  Blood       Date:  2008-07-30       Impact factor: 22.113

5.  Local interleukin-1-driven joint pathology is dependent on toll-like receptor 4 activation.

Authors:  Shahla Abdollahi-Roodsaz; Leo A B Joosten; Marije I Koenders; Ben T van den Brand; Fons A J van de Loo; Wim B van den Berg
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

Review 6.  Cytokine networks in systemic lupus erythematosus.

Authors:  Hooi-Ming Lee; Hidehiko Sugino; Norihiro Nishimoto
Journal:  J Biomed Biotechnol       Date:  2010-04-15

Review 7.  IL-17 as a future therapeutic target for rheumatoid arthritis.

Authors:  Wim B van den Berg; Pierre Miossec
Journal:  Nat Rev Rheumatol       Date:  2009-10       Impact factor: 20.543

Review 8.  Translational mini-review series on Th17 cells: are T helper 17 cells really pathogenic in autoimmunity?

Authors:  M I Koenders; W B van den Berg
Journal:  Clin Exp Immunol       Date:  2009-11-11       Impact factor: 4.330

9.  Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies.

Authors:  Ellen M Moran; Ronan Mullan; Jennifer McCormick; Mary Connolly; Owen Sullivan; Oliver Fitzgerald; Barry Bresnihan; Douglas J Veale; Ursula Fearon
Journal:  Arthritis Res Ther       Date:  2009-07-23       Impact factor: 5.156

10.  Infliximab in the treatment of rheumatoid arthritis.

Authors:  A Perdriger
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.